Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA5 | O75582 | 15/20 | 0.61 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.48 |
| ▸ | RPS6KA1 | Q15418 | 6/20 | 0.48 |
| ▸ | AKT1 | P31749 | 6/20 | 0.48 |
| ▸ | AKT2 | P31751 | 1/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL690731 | 0.86 | RPS6KA5 (0.63) | RPS6KA5SLC2A1ROCK1RPS6KA1AKT1 | |
| SCHEMBL14534949 | 0.86 | RPS6KA5 (0.61) | RPS6KA5SLC2A1ROCK1RPS6KA1AKT1 | |
| SCHEMBL4062121 | 0.82 | RPS6KA5 (0.69) | RPS6KA5ROCK1RPS6KA1AKT1RPS6KB1 | |
| SCHEMBL5067604 | 0.82 | RPS6KA5 (0.56) | RPS6KA5SLC2A1ROCK1RPS6KA1AKT1 | |
| SCHEMBL21350454 | 0.81 | AKT1 (0.73) | RPS6KA5SLC2A1ROCK1RPS6KA1AKT1 | |
| SCHEMBL4296943 | 0.80 | SLC2A1 (0.57) | RPS6KA5SLC2A1ROCK1RPS6KA1AKT1 | |
| SCHEMBL4295261 | 0.80 | AKT1 (0.61) | RPS6KA5SLC2A1ROCK1RPS6KA1AKT1 | |
| SCHEMBL14536483 | 0.79 | AKT1 (0.74) | RPS6KA5ROCK1RPS6KA1AKT1AKT2 | |
| SCHEMBL4247863 | 0.79 | ROCK1 (0.71) | RPS6KA5ROCK1RPS6KA1AKT1RPS6KB1 | |
| SCHEMBL5062751 | 0.78 | AKT1 (0.54) | RPS6KA5ROCK1RPS6KA1AKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2286232-B1 | METHODS FOR THE IDENTIFICATION OF PARP INTERACTING MOLECULES AND FOR PURIFICATION OF PARP PROTEINS | CELLZOME AG (DE) | 2012-02-29 | — | — | EP | disclosed |
| EP-2286232-B1 | METHODS FOR THE IDENTIFICATION OF PARP INTERACTING MOLECULES AND FOR PURIFICATION OF PARP PROTEINS | CELLZOME AG (DE) | 2012-02-29 | — | — | EP | disclosed |
| US-20110070595-A1 | METHODS FOR THE IDENTIFICATION OF PARP INTERACTING MOLECULES AND FOR PURIFICATION OF PARP PROTEINS | CELLZOME AG | 2011-03-24 | — | — | US | disclosed |
| US-20110070595-A1 | METHODS FOR THE IDENTIFICATION OF PARP INTERACTING MOLECULES AND FOR PURIFICATION OF PARP PROTEINS | CELLZOME AG | 2011-03-24 | — | — | US | disclosed |
| EP-2286232-A1 | METHODS FOR THE IDENTIFICATION OF PARP INTERACTING MOLECULES AND FOR PURIFICATION OF PARP PROTEINS | CELLZOME AG (DE) | 2011-02-23 | — | — | EP | disclosed |
| US-20100056523-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-20100056523-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-7625890-B2 | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors | SMITHKLINE BEECHAM CORP. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625890-B2 | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors | SMITHKLINE BEECHAM CORP. (US) | 2009-12-01 | — | — | US | disclosed |
| WO-2009138229-A1 | METHODS FOR THE IDENTIFICATION OF PARP INTERACTING MOLECULES AND FOR PURIFICATION OF PARP PROTEINS | CELLZOME AG (DE) | 2009-11-19 | — | — | WO | disclosed |
| US-20080255143-A1 | Inhibitors of Akt Activity | SMITHKLINE BEECHAM CORPORATION (PA) | 2008-10-16 | — | — | US | disclosed |
| US-20080255143-A1 | Inhibitors of Akt Activity | SMITHKLINE BEECHAM CORPORATION (PA) | 2008-10-16 | — | — | US | disclosed |
| WO-2008121685-A1 | METHODS OF USE FOR INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008063853-A2 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008063853-A2 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2008-05-29 | — | — | WO | disclosed |
| US-20080076763-A1 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC | 2008-03-27 | — | — | US | disclosed |
| US-20080076763-A1 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC | 2008-03-27 | — | — | US | disclosed |
| WO-2007058879-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058850-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058852-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076763-A1 | Inhibitors of Akt activity | PI4KB, PIK3CA, AKT2 | RPS6KA5 156/4885SLC2A1 3039/4885ROCK1 478/4885 |
| US-20110070595-A1 | METHODS FOR THE IDENTIFICATION OF PARP INTERACTING MOLECULES AND FOR PURIFICATION OF PARP PROTEINS | PARP3, PARP11, PARP12 | RPS6KA5 2006/4885SLC2A1 4443/4885ROCK1 2576/4885 |
| US-20100056523-A1 | INHIBITORS OF AKT ACTIVITY | PI4KB, PIK3CA, AKT2 | RPS6KA5 156/4885SLC2A1 3039/4885ROCK1 478/4885 |
| US-20080255143-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | RPS6KA5 156/4885SLC2A1 3039/4885ROCK1 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.